DE122010000011I1 - Flüssige gonadotropinhaltige Arzneimittel - Google Patents

Flüssige gonadotropinhaltige Arzneimittel

Info

Publication number
DE122010000011I1
DE122010000011I1 DE122010000011C DE122010000011C DE122010000011I1 DE 122010000011 I1 DE122010000011 I1 DE 122010000011I1 DE 122010000011 C DE122010000011 C DE 122010000011C DE 122010000011 C DE122010000011 C DE 122010000011C DE 122010000011 I1 DE122010000011 I1 DE 122010000011I1
Authority
DE
Germany
Prior art keywords
containing drugs
liquid gonadotropin
gonadotropin
liquid
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE122010000011C
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon NV filed Critical Organon NV
Publication of DE122010000011I1 publication Critical patent/DE122010000011I1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE122010000011C 1997-01-15 1998-01-13 Flüssige gonadotropinhaltige Arzneimittel Pending DE122010000011I1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97200099 1997-01-15

Publications (1)

Publication Number Publication Date
DE122010000011I1 true DE122010000011I1 (de) 2010-07-08

Family

ID=8227932

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69813322T Expired - Lifetime DE69813322T2 (de) 1997-01-15 1998-01-13 Flüssige gonadotropinhaltige Arzneimittel
DE122010000011C Pending DE122010000011I1 (de) 1997-01-15 1998-01-13 Flüssige gonadotropinhaltige Arzneimittel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69813322T Expired - Lifetime DE69813322T2 (de) 1997-01-15 1998-01-13 Flüssige gonadotropinhaltige Arzneimittel

Country Status (29)

Country Link
US (1) US5929028A (https=)
EP (2) EP0853945B1 (https=)
JP (1) JP4353549B2 (https=)
KR (1) KR100498531B1 (https=)
CN (1) CN1165341C (https=)
AR (1) AR011410A1 (https=)
AT (1) ATE237348T1 (https=)
AU (1) AU736339B2 (https=)
BR (1) BR9800323B1 (https=)
CA (1) CA2226803A1 (https=)
CZ (1) CZ297419B6 (https=)
DE (2) DE69813322T2 (https=)
DK (1) DK0853945T3 (https=)
ES (1) ES2196474T3 (https=)
FR (1) FR10C0024I2 (https=)
HU (1) HU227154B1 (https=)
ID (1) ID19499A (https=)
IL (1) IL122732A0 (https=)
LU (1) LU91655I2 (https=)
MX (1) MX9800438A (https=)
NO (3) NO322509B1 (https=)
NZ (1) NZ329572A (https=)
PL (1) PL190103B1 (https=)
PT (1) PT853945E (https=)
RU (1) RU2203086C2 (https=)
SA (1) SA98181124B1 (https=)
TR (1) TR199800062A2 (https=)
TW (1) TW518235B (https=)
ZA (1) ZA9883B (https=)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140984A0 (en) * 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
JP2007204498A (ja) * 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
CN1360506A (zh) * 1999-07-12 2002-07-24 格兰迪斯生物技术有限公司 生长激素配方
CZ303274B6 (cs) * 2000-02-22 2012-07-11 Merck Serono Sa Zpusob vycištení luteinizacního hormonu
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
AU2007200662A1 (en) * 2001-08-30 2007-03-08 Kirin-Amgen, Inc. L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
EP1346843A1 (en) * 2002-03-22 2003-09-24 Fuji Photo Film Co., Ltd. Image forming method
CA2518268C (en) 2003-03-04 2013-12-10 Aspenbio, Inc. Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using luteinizing hormone
DK1610822T4 (en) * 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
ES2358330T5 (es) * 2003-04-02 2018-12-03 Ares Trading S.A. Formulaciones farmacéuticas líquidas de FSH y LH junto con un tensioactivo no iónico
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1638595B1 (en) * 2003-06-20 2013-03-20 Ares Trading S.A. Freeze-dried fsh / lh formulations
JP4412989B2 (ja) * 2003-12-15 2010-02-10 株式会社日立製作所 複数の記憶システムを有するデータ処理システム
KR100587535B1 (ko) * 2004-02-04 2006-06-08 충남대학교산학협력단 재조합 ｈＦＳＨ 유전자 및 이를 내장하는 발현용 벡터
TWI369401B (en) * 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
WO2007056851A1 (en) * 2005-11-17 2007-05-24 Mount Sinai Hospital Compositions and methods for enhancing ovulation inducing agents
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20090261690A1 (en) * 2006-09-25 2009-10-22 Tomoaki Mashimo Ultrasonic wave handling device and a microscopic in-tube inspection system
KR20080106636A (ko) * 2007-06-04 2008-12-09 동아제약주식회사 사람 융모성 성선자극호르몬 함유 즉시 사용형 주사 용액
EP2170268A2 (en) * 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
DK2170942T3 (da) 2007-06-28 2013-11-04 Biogenerix Ag Fsh-producerende celleklon
BRPI0818324B8 (pt) * 2007-11-01 2021-05-25 Merck Serono Sa formulação líquida contendo hormônio luteinizante (lh) ou uma variante do mesmo, seu uso, sua forma de apresentação, processo para a sua preparação e composição farmacêutica
NZ586588A (en) * 2008-02-08 2012-10-26 Biogenerix Ag Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
CN101347613B (zh) * 2008-09-17 2011-10-26 上海天伟生物制药有限公司 几乎不含亚基的糖蛋白的组合物及其制备方法
CN102309745B (zh) * 2008-09-17 2013-05-08 上海天伟生物制药有限公司 一种卵泡刺激素冻干针剂
KR101668502B1 (ko) 2008-11-04 2016-10-21 아스카 세이야쿠 가부시키가이샤 난포자극호르몬 함유 수성 조성물
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2325194A1 (en) 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012127500A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for spermatogenesis
WO2012127501A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for improving endometrial thickness during ovarian stimulation
PL2691119T3 (pl) 2011-03-31 2019-01-31 Ferring B.V. Preparat farmaceutyczny
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
US20120265129A1 (en) 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
BR112014001274A2 (pt) 2011-07-18 2017-04-18 Arts Biologics As composto de hormônio luteinizante, e, composição farmacêutica
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
HK1207564A1 (en) 2012-04-19 2016-02-05 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
WO2014063071A1 (en) 2012-10-18 2014-04-24 Neuralight Hd, Llc Treatment of depression and ptsd
HUE055348T2 (hu) 2012-11-20 2021-11-29 Opko Biologics Ltd Eljárás polipeptidek hidrodinamikus térfogatának növelésére gonadotropin karboxil-terminális peptidekhez való kapcsolással
EP2974734B1 (en) 2013-03-12 2018-10-10 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
AP2016009159A0 (en) 2013-11-12 2016-04-30 Cadila Healthcare Ltd Formulation for gonadotropins
DK3209319T3 (da) * 2014-10-21 2021-10-04 Hexima Ltd En fremgangsmåde til behandling af svampeinfektioner
EP3230309B1 (en) 2014-12-10 2023-03-29 OPKO Biologics Ltd. Methods of producing long acting ctp-modified growth hormone polypeptides
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
PL3310347T3 (pl) 2015-06-19 2021-12-27 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i sposoby wytwarzania
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
MY206271A (en) 2016-07-11 2024-12-06 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
CA3140267A1 (en) 2019-05-16 2020-11-19 Ceva Sante Animale Compositions and methods for increasing reproduction performance in non-human mammals using recombinant luteinizing hormone
CN114404575A (zh) * 2020-12-07 2022-04-29 苏州智核生物医药科技有限公司 一种重组人促甲状腺素注射液
CN117783545B (zh) * 2023-12-28 2026-03-06 深圳市新产业生物医学工程股份有限公司 经封闭剂封闭的软质材料、容器、液态校准品及检测试剂盒

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357934A (en) * 1980-07-23 1982-11-09 The Curators Of The University Of Missouri Method of treating male infertility
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
IT1206302B (it) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5338835A (en) * 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
JP3045539B2 (ja) * 1989-02-21 2000-05-29 ワシントン ユニバーシティ 改変型生殖ホルモン
US5114948A (en) * 1989-10-19 1992-05-19 Eli Lilly And Company Stabilized pergolide compositions
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
EP0639202B1 (en) * 1992-04-30 1998-11-25 Cor Therapeutics, Inc. Stable polypeptide composition
US5281198A (en) * 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
RU2062619C1 (ru) * 1994-02-08 1996-06-27 Курский сельскохозяйственный институт им.проф.И.И.Иванова Способ получения препарата фолликулостимулирующего гормона из аденогипофизов животных
PT814841E (pt) * 1995-03-21 2002-03-28 Applied Research Systems Formulacoes liquidas de hcg

Also Published As

Publication number Publication date
NO980177L (no) 1998-07-16
PL190103B1 (pl) 2005-10-31
RU2203086C2 (ru) 2003-04-27
AU736339B2 (en) 2001-07-26
NZ329572A (en) 1999-05-28
FR10C0024I2 (fr) 2011-04-01
ZA9883B (en) 1998-07-08
HUP9800056A3 (en) 2001-01-29
NO322509B1 (no) 2006-10-16
HU9800056D0 (en) 1998-03-02
CA2226803A1 (en) 1998-07-15
DE69813322D1 (de) 2003-05-22
AU5205998A (en) 1998-07-23
JP4353549B2 (ja) 2009-10-28
ID19499A (id) 1998-07-16
HU227154B1 (en) 2010-08-30
DK0853945T3 (da) 2003-08-04
PT853945E (pt) 2003-08-29
DE69813322T2 (de) 2004-02-19
CN1191139A (zh) 1998-08-26
NO2010013I2 (no) 2015-05-18
CZ297419B6 (cs) 2006-12-13
LU91655I2 (fr) 2010-04-26
NO980177D0 (no) 1998-01-14
EP0853945A1 (en) 1998-07-22
KR100498531B1 (ko) 2005-09-30
NO2010013I1 (no) 2010-06-07
MX9800438A (es) 1998-11-30
CZ13598A3 (cs) 1998-08-12
HUP9800056A2 (hu) 1998-08-28
EP0853945B1 (en) 2003-04-16
ES2196474T3 (es) 2003-12-16
IL122732A0 (en) 1998-08-16
ATE237348T1 (de) 2003-05-15
BR9800323B1 (pt) 2011-04-19
US5929028A (en) 1999-07-27
AR011410A1 (es) 2000-08-16
JPH10203997A (ja) 1998-08-04
HK1010150A1 (en) 1999-06-17
TW518235B (en) 2003-01-21
TR199800062A2 (xx) 1998-08-21
PL324279A1 (en) 1998-07-20
KR19980070493A (ko) 1998-10-26
CN1165341C (zh) 2004-09-08
SA98181124B1 (ar) 2006-07-10
NO2021001I1 (no) 2021-01-12
BR9800323A (pt) 1999-06-29
EP1285665A1 (en) 2003-02-26
FR10C0024I1 (https=) 2010-05-21

Similar Documents

Publication Publication Date Title
DE122010000011I1 (de) Flüssige gonadotropinhaltige Arzneimittel
ATE187063T1 (de) Arzneimittel
DE69737936D1 (de) Arzneimittel
NO20001776D0 (no) Medikamenter
DE69908021D1 (de) Ziprasidonhaltige Arzneimittel
ID24654A (id) Formulasi farmasi omeprazola
DE69629755D1 (de) Irbesartanhaltiges Arzneimittel
DK0998272T3 (da) Farmaceutisk præparat til kombinationen piperidinoalkanoldekongestivum
FI973243L (fi) Uusi farmaseuttinen yhdistelmä
IS4974A (is) Lyfjasamsetning á þrýstingsúðaformi
NO980546D0 (no) Farmasöytiske midler
DE69813602D1 (de) Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe
DE69812708D1 (de) Neue arzneimittel enthaltend uridintriphosphat
DK1017392T3 (da) Lægemiddel
ID27150A (id) Sediaan levotiroksin bahan farmasi
DE69926012D1 (de) Arzneizubereitungen
NO994619D0 (no) Farmasöytiske blandinger
NO20003141D0 (no) Farmasøytiske blandinger
DE69906934D1 (de) Arzneizubereitungen
DE59805373D1 (de) Nephroprotektive Arzneimittel
DE69904021D1 (de) Flüsige pharmazeusche zubereitung enthaltend zotepin
DE69819203D1 (de) Trinkbares arzneimittel
FI3163U1 (fi) Lääkesäiliö
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste
UA25523A (uk) Лікувальhий препарат гірчичhик